Opendata, web and dolomites

PDPcardio SIGNED

Protein phosphatase 1-disrupting peptides: Scope and mechanism of action in the treatment of heart insufficiency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PDPcardio project word cloud

Explore the words cloud of the PDPcardio project. It provides you a very rough idea of what is the project "PDPcardio" about.

ryr2    insufficiency    fundamental    implicated    dephosphorylate    ubiquitously    basis    holoenzymes    serines    signaling    synthetic    therapeutic    biology    unknown    combined    homoeostasis    reticulum    pdpcardio    counteracts    hard    lies    seals    hyperactivity    arrhythmogenic    pdp    cardiomyocytes    pp1    guide    play    chemical    accordingly    cells    effect    catalytic    drugs    human    ligands    beneficial    interaction    bound    fine    applicable    scope    phosphatase    tools    substrates    proteins    roles    deregulation    subunit    nevertheless    heart    indicated    receptor    pdps    tissue    dephosphorylation    physiological    tune    release    potentially    dysfunctions    proteomics    pp1c    disrupting    amount    protein    data    regulatory    selectively    generally    threonines    treatment    peptides    mechanistic    interactions    strategies    powerful    showed    calcium    leak    unclear    tool    mechanisms    ryanodine    mediated    kinase    regulation    phosphorylated    sarcoplasmic    pathologies    enzyme    sr    action    principles    expressed    cardiac    underlying   

Project "PDPcardio" data sheet

The following table provides information about the project.

Coordinator
ALBERT-LUDWIGS-UNIVERSITAET FREIBURG 

Organization address
address: FAHNENBERGPLATZ
city: FREIBURG
postcode: 79098
website: www.uni-freiburg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙998˙750 €
 EC max contribution 1˙998˙750 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-COG
 Funding Scheme ERC-COG
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2025-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ALBERT-LUDWIGS-UNIVERSITAET FREIBURG DE (FREIBURG) coordinator 1˙998˙750.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Protein phosphatase-1 (PP1) is a ubiquitously expressed enzyme known to dephosphorylate a large number of the phosphorylated serines and threonines. The catalytic subunit PP1c is bound to regulatory proteins in holoenzymes. These play specific and fundamental roles in physiological processes and pathologies. One key role lies in the regulation of important cardiac signaling pathways and calcium homoeostasis. Accordingly, deregulation of PP1 has been implicated in cardiac dysfunctions. Powerful tools to study PP1 biology are our own developed PP1-disrupting peptides (PDPs) that selectively release PP1c (bound to PDP: PDP–PP1c) activity in cells. Recently, we showed that PDP treatment counteracts kinase hyperactivity and seals the arrhythmogenic sarcoplasmic reticulum (SR)-calcium-leak in human heart failure tissue. Mechanistic data indicated that PDP–PP1c-mediated dephosphorylation of the ryanodine receptor type 2 (RyR2) is involved in this effect. Nevertheless, given the large amount of potential PP1 substrates, so far the scope of PDP action is unknown, and therefore the mechanisms underlying this beneficial and potentially therapeutic effect of the PDPs in heart failure are unclear and currently hard to investigate. PDPcardio will address these challenges by providing new chemical biology methodologies combined with proteomics approaches using PDPs to guide PP1c to its substrates and to identify PDP-mediated interactions of PP1. These strategies will enable identifying the scope of PDP action in general, and in particular they will be applied here in cardiomyocytes to study the effects of PDP–PP1c. The results will provide the basis to fine-tune targeting PP1 for the treatment of heart insufficiency. Furthermore, the principles and methods developed here will be applicable more generally for defining the interaction scope of target-bound ligands (drugs) as well as for using PP1 as tool in synthetic biology.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PDPCARDIO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PDPCARDIO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

Diverge (2019)

Generation of ultra-deep libraries of transcriptional activators for gene therapy

Read More  

inSight (2019)

Moving a novel gene therapy paradigm to treat blindness to the market

Read More  

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More